Tower Research Capital (TRC)’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.51K | Buy |
27,607
+6,558
| +31% | +$1.94K | ﹤0.01% | 4129 |
|
|
2026
Q1 | $5.54K | Buy |
21,049
+6,657
| +46% | +$1.85K | ﹤0.01% | 4109 |
|
|
2025
Q4 | $4.05K | Buy |
14,392
+4,599
| +47% | +$1.64K | ﹤0.01% | 4268 |
|
|
2025
Q3 | $4.08K | Sell |
9,793
-2,106
| -18% | -$801 | ﹤0.01% | 4407 |
|
|
2025
Q2 | $3.64K | Sell |
11,899
-1,454
| -11% | -$437 | ﹤0.01% | 4459 |
|
|
2025
Q1 | $3.81K | Buy |
13,353
+2,310
| +21% | +$729 | ﹤0.01% | 4346 |
|
|
2024
Q4 | $3.71K | Buy |
11,043
+547
| +5% | +$205 | ﹤0.01% | 4608 |
|
|
2024
Q3 | $4.48K | Buy |
10,496
+2,478
| +31% | +$993 | ﹤0.01% | 4532 |
|
|
2024
Q2 | $3.48K | Sell |
8,018
-5,636
| -41% | -$2.8K | ﹤0.01% | 4885 |
|
|
2024
Q1 | $5.46K | Sell |
13,654
-9,663
| -41% | -$3K | ﹤0.01% | 4539 |
|
|
2023
Q4 | $6.53K | Buy |
23,317
+1,982
| +9% | +$614 | ﹤0.01% | 4728 |
|
|
2023
Q3 | $7.66K | Buy |
21,335
+654
| +3% | +$234 | ﹤0.01% | 4446 |
|
|
2023
Q2 | $6.45K | Sell |
20,681
-114
| -0.5% | -$37 | ﹤0.01% | 4703 |
|
|
2023
Q1 | $7K | Buy |
20,795
+10,703
| +106% | +$4.01K | ﹤0.01% | 4741 |
|
|
2022
Q4 | $3K | Buy |
+10,092
| New | +$4.12K | ﹤0.01% | 5195 |
|
|
2022
Q2 | – | Sell |
-1,364
| Closed | -$1K | – | 6270 |
|
|
2022
Q1 | $1K | Buy |
1,364
+968
| +244% | +$940 | ﹤0.01% | 5804 |
|
|
2021
Q4 | $0 | Buy |
+396
| New | +$531 | ﹤0.01% | 6330 |
|
|
2021
Q1 | – | Sell |
-28,742
| Closed | -$45K | – | 5535 |
|
|
2020
Q4 | $45K | Buy |
28,742
+23,987
| +504% | +$35.4K | ﹤0.01% | 3213 |
|
|
2020
Q3 | $5K | Buy |
+4,755
| New | +$4.83K | ﹤0.01% | 4357 |
|
|
2015
Q3 | – | Sell |
-43
| Closed | – | – | 4349 |
|
|
2015
Q2 | $0 | Hold |
43
| – | – | ﹤0.01% | 4672 |
|
|
2015
Q1 | $0 | Sell |
43
-91
| -68% | -$49 | ﹤0.01% | 4643 |
|
|
2014
Q4 | $0 | Hold |
134
| – | – | ﹤0.01% | 4309 |
|
|
2014
Q3 | $0 | Hold |
134
| – | – | ﹤0.01% | 4621 |
|
|
2014
Q2 | $0 | Buy |
134
+27
| +25% | +$31 | ﹤0.01% | 4309 |
|
|
2014
Q1 | $0 | Buy |
107
+93
| +664% | +$81 | ﹤0.01% | 4659 |
|
|
2013
Q4 | $0 | Buy |
14
+7
| +100% | +$6 | ﹤0.01% | 4682 |
|
|
2013
Q3 | $0 | Sell |
7
-218
| -97% | -$272 | ﹤0.01% | 4670 |
|
|
2013
Q2 | $0 | Buy |
+225
| New | +$472 | ﹤0.01% | 3943 |
|
Other funds holding IGC
AI
LC
Tower Research Capital (TRC)'s IGC Position: Q2 2026 in Review
Tower Research Capital (TRC) increased its IGC Pharma (IGC) stake by 31% in Q2 2026, buying an estimated $1.94K and bringing the position to 27,607 shares worth $7.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.
Tower Research Capital (TRC) first reported a position in IGC in Q2 2013 and has held it in 28 quarters since. The position peaked at $45K in Q4 2020. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.
- Tower Research Capital (TRC) held 27,607 shares of IGC Pharma worth $7.51K as of Q2 2026.
- Tower Research Capital (TRC) bought 6,558 IGC Pharma shares in Q2 2026, an estimated $1.94K.
- IGC Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4129 holding.
- Tower Research Capital (TRC) first reported a position in IGC Pharma in Q2 2013 and has held it in 28 quarters since.
- Tower Research Capital (TRC)'s IGC Pharma position peaked at $45K in Q4 2020.
- 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.